●津药药业股份有限公司（以下简称"公司"）子公司湖北津药药业股份有 限公司（以下简称"湖北津药"）委托天津药业研究院股份有限公司（以下简称 "药研院"）开展 X23、X24、X25、X26、Y22 等五个项目的药学研究工作，双方 签署《技术开发（委托）合同》，金额合计为 1,530 万元。 ●截至本公告日，公司及子公司过去 12 个月内发生的与同一关联人及与不 同关联人交易类别相关的交易共计五次，金额为 4,180 万元，均已单独履行审批 程序。以上金额不超过公司最近一期经审计净资产的 5%，本次关联交易无需提 交公司股东大会审议。 ●本次交易将进一步丰富公司产品结构，增强公司在制剂产品方面的技术实 力和核心竞争力，有利于公司的可持续发展。独立董事对上述关联交易进行了事 前认可并发表了独立意见，关联董事均已回避表决。 一、 关联交易概述 证券代码：600488 证券简称：津药药业 编号：2023-061 津药药业股份有限公司 子公司与天津药业研究院股份有限公司关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 ...

Group 1: Company Overview and Event Participation - Tianjin Pharmaceutical Co., Ltd. participated in the 2023 Annual Tianjin Listed Companies Half-Year Report Performance Briefing on September 5, 2023 [2][3] - The event was organized by Tianjin Securities Regulatory Bureau, Tianjin Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [2] Group 2: Financial Performance and R&D Investment - In the first half of 2023, the company's R&D expenses amounted to approximately CNY 84.93 million, representing a year-on-year increase of 23.10% [4] - The company's revenue from steroid hormone business reached CNY 1.086 billion, with a year-on-year growth of 17.98% [9] Group 3: Market Presence and Product Strategy - The company has established a strong international market presence, with raw material drug sales covering over 70 countries and regions [5][9] - The company aims to expand its global vision and focus on high-end markets in Europe and America while accelerating the international registration of new products in emerging markets [5] Group 4: Product Portfolio and Market Share - Major products include over 40 types of steroid hormone raw materials and 23 types of amino acid raw materials, with several achieving over CNY 100 million in sales in 2022 [11] - The company’s prednisone tablets ranked first in market share in the U.S. for two consecutive years (2021-2022) [7][8] Group 5: Cash Flow and Financial Health - The net cash flow from operating activities exceeded CNY 313 million in the first half of 2023, reflecting a year-on-year increase of 39.52% [15]

津药药业股份有限公司 独立董事候选人声明 本人陈喆，已充分了解并同意由提名人天津药业集团有限公司提 名为津药药业股份有限公司（以下简称"津药药业"）第九届董事会 独立董事候选人。本人公开声明，本人具备独立董事任职资格，保证 不存在任何影响本人担任津药药业独立董事独立性的关系，具体声明 如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有5年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明材料。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司 规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （六）中共中央纪委、教育部、监察部《关于加强高等学校反腐 倡廉建设的意见》的相关规定（如适用）； （七）中国人民银行《股份制商业银行独立董事和外部监事制度 1 / 4 指引》等的相关规定（如适用）； （八）中国证监会《证券基金经营机构董事、监事、高级管理人 员及从业人员监督管理办法》等的相关规定（ ...

津药药业股份有限公司 独立董事候选人声明 本人霍文逊，已充分了解并同意由提名人天津药业集团有限公司 提名为津药药业股份有限公司（以下简称"津药药业"）第九届董事 会独立董事候选人。本人公开声明，本人具备独立董事任职资格，保 证不存在任何影响本人担任津药药业独立董事独立性的关系，具体声 明如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法 规、部门规章及其他规范性文件，具有5年以上法律、经济、会计、 财务、管理或者其他履行独立董事职责所必需的工作经验。 本人已经参加培训并取得证券交易所认可的相关培训证明材料。 （二）《中华人民共和国公务员法》关于公务员兼任职务的规定 （如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证券交 易所自律监管规则以及公司章程有关独立董事任职资格和条件的相 关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去 公职或者退（离）休后担任上市公司、基金管理公司独立董事、独立 监事的通知》的规定（如适用）； （五）中共中央组织部《关于进一步规范党政领导干部在企业兼 职（任职）问题的意见》的相关规定（如适用）； （六）中共中央纪委、教育部、监察部《关于 ...

公司章程 津药药业股份有限公司章程 二○二三年九月 （2023 年 9 月 6 日经公司第八届董事会第三十三次会议审议通过） 1 / 49 | 目录 | | --- | | 第一章 | 总 则 3 | | --- | --- | | 第二章 | 经营宗旨和范围 6 | | 第三章 | 股 份 7 | | 第一节 | 股份发行 7 | | 第二节 | 股份增减和回购 8 | | 第三节 | 股份转让 9 | | 第四章 | 股东和股东大会 10 | | 第一节 | 股 东 10 | | 第二节 | 股东大会的一般规定 12 | | 第三节 | 股东大会的召集 14 | | 第四节 | 股东大会的提案与通知 15 | | 第五节 | 股东大会的召开 17 | | 第六节 | 股东大会的表决和决议 19 | | 第五章 | 党的组织 23 | | 第六章 | 董事会 24 | | 第一节 | 董 事 24 | | 第二节 | 独立董事 26 | | 第三节 | 董事会 30 | | 第四节 | 董事会秘书 34 | | 第七章 | 总经理及其他高级管理人员 37 | | 第八章 | 监事会 38 | | 第一节 | ...

证券代码：600488 证券简称：津药药业 编号：2023-058 津药药业股份有限公司 关于选举第九届监事会职工代表监事的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 附件： 职工监事简历 1.李娟，女，1980 年出生，中国农工民主党，大学本科学历， 高级统计师。历任公司 107 车间统计员、质检员、质量控制部统计 员，天津药业集团有限公司综合计划部部长助理、战略发展部部长。 现任公司战略运营部部长。 2.池永艳，女，1973 年出生，中共党员，大学本科学历，会计 师。历任天津天安药业股份有限公司财务部长，天津万宁保健品有 限公司财务部长、财务总监，天津格斯宝药业有限公司财务总监。 现任公司审计专员。 津药药业股份有限公司(以下简称"公司")第八届监事会将届满， 根据《公司法》及《公司章程》的有关规定，公司于 2023 年 9 月 4 日召开 2023 年第三次职工代表大会，通过职工民主选举，选举池永 艳女士、李娟女士为公司第九届监事会职工监事，行使监事权利， 履行监事义务。 本次选举产生的2名职工监事将与公 ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2023, representing a year-on-year increase of 15%[19]. - The net profit attributable to shareholders reached RMB 100 million, up 20% compared to the same period last year[19]. - The company's operating revenue for the first half of the year reached ¥2,023,258,856.62, representing a year-on-year increase of 12.26% compared to ¥1,802,329,294.96[20]. - Net profit attributable to shareholders increased by 102.88% year-on-year, amounting to ¥123,405,359.07, driven by increased market demand and improved internal management[21]. - The basic earnings per share rose to ¥0.113, reflecting a growth of 101.79% compared to ¥0.056 in the same period last year[21]. - The net cash flow from operating activities increased by 39.52% year-on-year, totaling ¥313,762,491.73, due to higher revenue and improved management of customer accounts[22]. - The company achieved a total revenue of RMB 2.004 billion in the first half of 2023, with a gross margin of 51.18%[44]. - The revenue from steroid hormone products was RMB 1.086 billion, with a gross margin of 33.81%, reflecting an increase of 2.46 percentage points year-on-year[45]. - The amino acid product revenue was RMB 198 million, with a gross margin of 54.79%, showing a year-on-year decrease of 5.12%[45]. - The company reported a significant increase in prepayments, rising to RMB 30.49 million from RMB 15.41 million, an increase of approximately 97.5%[152]. - The company reported a total comprehensive income of ¥77.33 million for the first half of 2023, compared to ¥44.48 million in the same period last year, marking a 73.94% increase[165]. Market Expansion and Product Development - User data indicates a growth in active users by 25%, reaching a total of 1 million active users by the end of June 2023[19]. - The company plans to launch two new products in Q3 2023, aiming to capture an additional 10% market share in the pharmaceutical sector[19]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a revenue contribution of 5% from this region by the end of 2024[19]. - A strategic acquisition of a local biotech firm is under consideration, which could enhance the company's product pipeline and market presence[19]. - The company is focusing on the development of new products, including several injection solutions that have achieved domestic firsts in consistency evaluation[29]. - The company plans to leverage its integrated advantages in steroid and amino acid raw materials to drive future growth and product development[29]. - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[155]. Research and Development - Research and development expenses increased by 30%, totaling RMB 50 million, reflecting the company's commitment to innovation[19]. - The company has strengthened its marketing strategies, expanding sales regions and customer bases, particularly in the export markets[29]. - The company is committed to enhancing R&D investment and expanding its global market presence to strengthen competitiveness[36]. - Research and development expenses rose by 23.10% to ¥84,927,699.54, up from ¥68,992,390.17 in the previous year[51]. - The company is focusing on lean production to enhance efficiency and reduce costs, with ongoing safety automation upgrades in its raw material production lines[47]. - The company will continue to increase investment in technology research and development to maintain its leading position in the industry[83]. Financial Stability and Risks - The company's total assets decreased by 2.02% to ¥6,516,513,806.01 from ¥6,650,699,943.31 at the end of the previous year[20]. - The weighted average return on equity increased by 2.06 percentage points to 4.07% from 2.01% year-on-year[21]. - The company faces risks related to raw material price increases, supply shortages, and logistics disruptions, with plans to mitigate these risks through supplier diversification and inventory management[82]. - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[19]. - The company has no non-operational fund occupation by controlling shareholders or related parties during the reporting period[19]. Environmental Compliance and Initiatives - The company has continuously increased its investment in environmental protection, with energy consumption in the first half of 2023 reported as 11,593,700 kWh of electricity and 14,248.7 tons of standard coal[98]. - The company has implemented real-time monitoring of key environmental indicators through its SCADA data management platform to ensure compliance with environmental standards[84]. - The company has not reported any major environmental issues during the reporting period and is committed to fulfilling its environmental and social responsibilities[98]. - The company has established an EHS policy to integrate safety and environmental protection into its operations[98]. - The company is committed to sustainable development, balancing environmental and economic benefits through continuous improvements in production processes[114]. Shareholder and Equity Structure - The company has 18 companies under its control, including 11 subsidiaries and 7 associated companies[57]. - The company’s shareholder structure changed with Bohai State Capital increasing its stake in the pharmaceutical group to 33%[136]. - The top ten shareholders collectively held 77.88% of the total shares, indicating a high concentration of ownership[146]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period[148]. - The company’s total number of restricted stocks remaining after repurchases is 2,046,000 shares[141]. Compliance and Legal Matters - The company’s subsidiary, Jinyao Pharmaceutical, was fined ¥27,721,311.36 for abusing its dominant market position in the Carmustine injection market[119]. - The company’s subsidiary, Pharmaceutical Technology, was fined ¥29,884,312.48 for price-fixing and market division agreements related to Fluorouracil injection sales[120]. - The company has implemented compliance training and adjusted sales strategies to ensure market supply and maintain compliance with antitrust laws[120]. - The company has actively participated in provincial bulk purchasing projects for Fluorouracil injection, aligning with local pricing policies[121].

证券代码：600488 证券简称：津药药业 编号：2023-054 津药药业股份有限公司 关于参加 2023 年度天津辖区上市公司半年报业绩说 明会暨投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●会议召开时间：2023年9月5日(周二)13:30-16:50 ●会议召开地点：全景路演 ●会议召开方式：网络远程互动 一、会议类型 津药药业股份有限公司（以下简称"公司"）已于2023年8月30 日发布公司2023年半年度报告，为进一步加强与投资者的互动交流， 公司将参加由天津证监局、天津上市公司协会与深圳市全景网络有限 公司联合举办的"2023年度天津辖区上市公司半年报业绩说明会暨 投资者网上集体接待日活动"。公司将在信息披露允许的范围内就投 资者普遍关注的问题进行回答。 二、会议召开时间、地点 （一）会议召开时间：2023年9月5日（周二）13:30-16:50 （二）会议召开地点：全景路演 （三）会议召开方式：网络远程互动 三、公司出席人员 公司出席本次活动的人员有： ...